Niagen Bioscience (NAGE) Insider JR Buys 31,746 Shares
Jaksch Frank Jr. purchased 31,746 shares of Niagen Bioscience on June 24, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jaksch Frank JR bought 31,746 shares of Niagen Bioscience, Inc. ($NAGE) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NAGE is down 3.5% after 1 week, down 7.0% after 1 month and down 27.8% to date (from the $3.45 close on Jun 24, 2026).
NAGE
Niagen Bioscience, Inc.
Key Points
- On June 24, 2026, Jaksch Frank Jr. bought 31,746 shares of Niagen Bioscience, Inc. at a price of $3.42 per share.
- The stock is currently trading near its 52-week low of $2.87, which may attract investor interest.
- Niagen Bioscience has a market cap of about $240.5 million and is in the consumer defensive sector.
Get $NAGE trade alerts by text
We text you when insiders, Congress or big funds trade $NAGE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Niagen Bioscience, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Niagen Bioscience, Inc.
Jaksch Frank Jr. bought 31,746 shares of Niagen Bioscience, Inc. (NAGE) on June 24, 2026. The shares were purchased at a price of $3.42 each, reflecting a total investment value based on the current market price. This purchase comes as the stock trades close to its 52-week low of $2.87, which may signal a strategic move considering its recent performance.
Other Insiders Also Active
On the same day, several other insiders made similar purchases. Yu Wing Tak Wendy, Hamed Shahbazi, Steven Rubin, Kristin Patrick, Ann Cohen, and Ng Wang Yu Gary each acquired 31,746 shares of Niagen Bioscience as well. This coordinated buying activity among insiders might indicate a shared confidence in the company's future prospects.
Stock Performance Context
Currently, Niagen Bioscience's stock is trading at $3.42, which is near its 52-week low of $2.87. The stock previously closed at $2.99, indicating some volatility in recent trading sessions. The company's market cap stands at approximately $240.5 million, and it has a P/E ratio of 16.0, suggesting it is viewed as profitable compared to many peers in the packaged foods industry.
What Niagen Bioscience, Inc. Does
Niagen Bioscience, Inc. focuses on developing products aimed at promoting healthy aging. The company specializes in nicotinamide adenine dinucleotide (NAD+), which is important for cellular metabolism, and markets supplements under the NIAGEN brand. It operates in the consumer defensive sector and is headquartered in Los Angeles, California.
What's Ahead for Niagen Bioscience, Inc.
Investors will be watching Niagen Bioscience closely, especially with its next earnings report scheduled for November 3, 2026. The recent insider buying activity provides an interesting context as the company continues to navigate its market position. This insider trading reflects past decisions and may not indicate current strategies, but it does highlight the confidence of those close to the company as it approaches its upcoming earnings date.
Related Filing Alerts
Source: Jaksch Frank JR's Form 4 filing on $NAGE (Jun 24, 2026). Find the original filing: NAGE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts